Many people think that hepatitis B can not be cured, and there is no obvious symptoms, so there is no need to treat, and even think that the treatment of hepatitis B is a pure waste of time and money. Experts point out that this view is very wrong. Hepatitis B is the main cause of chronic liver disease, cirrhosis and primary liver cancer, if left unchecked, the harm can not be underestimated. July 28, 2011 is the first officially recognized by the World Health Organization World Hepatitis Day, but also recognized by the World Health Organization’s fourth disease day, the theme is “this is hepatitis ……”, aimed at letting more people realize the harm of hepatitis, attention. Globally, 1 million people die of hepatitis B-related diseases every year Currently, 2 billion people around the world have been infected with the hepatitis B virus, and there are about 350 million hepatitis B carriers, of which the Asia-Pacific region accounted for two thirds, and 120 million people in China are carrying hepatitis B. The Chinese Academy of Engineering academician Zhuang Hui has been recently recognized by the World Health Organization as the fourth disease day. Zhuang Hui, an academician of the Chinese Academy of Engineering, recently pointed out at the first Asia-Pacific Frontier Liver Disease Forum that chronic hepatitis B is a serious global public health problem, and about 1 million patients die of hepatitis B-related diseases every year, which is the seventh leading cause of death in the world. “From the source of the disease, chronic hepatitis B is an immune-mediated disease”, academician Zhuang Hui graphically described: “Chronic hepatitis B is a war between the body’s immune system and the hepatitis B virus, both sides of the fierce battle, leaving the liver with a broken wall, so that a large number of liver cells are damaged, dead, if the war is more and more intense, it will take a long time for the liver cells to be damaged and die. If the war intensifies and lasts for a long time, it will lead to liver fibrosis, cirrhosis and even liver cancer.” Quantitative monitoring of e/s antigen is a “weathervane” for the efficacy of treatment. How to know whether the treatment is effective? In fact, e/s antigen conversion is the doctor’s efficacy observation “wind vane”. In the course of treatment, doctors commonly monitor the patient’s indicators are mainly three: the first indicator is the e antigen. e antigen is produced by the hepatitis B virus, e antigen positive, the virus replication is more active. The second indicator is the level of hepatitis B DNA, which shows the amount of hepatitis B virus in the patient’s body. The third indicator is transaminase, which reflects the level of liver inflammation. Li-Yuan Chen, director of the Liver Care Center at The Chinese University of Hong Kong, pointed out that “if a person’s own immunity can control the hepatitis B virus, the e antigen in the serum disappears, and the e antibody appears, then the number of hepatitis B virus is very low, and at the same time liver inflammation also disappears, which is also known as the immune control, and the immune control is the pathway to achieve the clinical cure of chronic hepatitis B. Immunologic control is the way to achieve a clinical cure for chronic hepatitis B. ” Therefore, there are gold, silver and bronze medals for hepatitis B treatment goals. Chen Liyuan said that the bronze medal goal is to inhibit viral replication; silver medal goal is e antigen conversion, the current goal of drug withdrawal, that is, to achieve lasting immune control; gold medal goal is s antigen clearance, conversion, to achieve a clinical cure, only through the interferon treatment can be obtained. Chen Liyuan believes that the longer the immune control period, the better, so that there is no damage to the liver. Through long-term follow-up, it is also understood that these patients have a lower chance of developing cirrhosis and liver cancer. No relapse after stopping medication is the latest treatment idea Many hepatitis B patients have a worry that hepatitis B treatment requires lifelong medication. In fact, experts pointed out that lasting immune control can make chronic hepatitis B patients not to relapse after stopping medication. According to Beijing Ditan Hospital Liver Disease Center deputy chief physician Li Minghui introduction, the current treatment of chronic hepatitis B drugs are mainly divided into two categories: a class of nucleoside (acid) analogues, with inhibition of viral DNA replication; the other is a long-acting interferon class, with antiviral and immune regulation of the dual role. In the battle between the immune system and hepatitis B virus, nucleoside (acid) analogs are designed to reduce the number of viruses, suppress the virus during the period of medication, but once the medication is discontinued, the disease will come back, so it is necessary to take medication for a long period of time, and at the same time, there is the possibility of viral resistance during the course of treatment. Since it does not kill liver cells, although it does not damage liver function, it is also difficult to completely eliminate the hepatitis B virus. Long-acting interferon is a two-pronged approach, on the one hand, to reduce the number of viruses, and on the other hand, it is aimed at the source of the disease, stimulate the body’s immune ability, so that after the end of a limited course of treatment, the disease can still be controlled for a long time, and will not be resurrected. Therefore, relatively more patients will turn from “big triple yang” to “small triple yang” after treatment, and some of them may also have surface antigen turned negative and will not relapse after stopping the drug. Therefore, it is recommended that young patients start their antiviral therapy with interferon. Patients should choose the right drugs for themselves under the guidance of professional doctors according to different situations.” Li Minghui reminded patients and their families that there are many small advertisements misleading patients, such as “one shot to turn negative”, “ten days to cure hepatitis B”, and “one day to cure hepatitis B”. Ten days to cure hepatitis B” and so on. Li Minghui emphasized that the treatment of hepatitis B can not be completed overnight, need to be adhered to through a period of time, so patients should not believe in rumors, so as not to delay the condition.